MedElevator Войти в исследования
← Поиск публикаций

DOI 10.7759/cureus.45455

Медицинская библиотека · Cureus · 2023

A Case of Pembrolizumab-Induced Myasthenia Gravis.

Kosick Thomas I, Patel Krima, Jasinski Jacob, Dada Bolanle

Клинический случайСтатьяПеревод в очереди

Аннотация

With the advent of new cancer treatments, immunotherapy has emerged as an increasingly promising strategy. Undoubtedly, it has pushed oncology into a new era and is providing patients with unprecedented results. As with many treatments, however, adverse effects lead to setbacks in progress. Pembrolizumab is an immunomodulating medication that functions by binding to programmed cell death protein 1 (PD-1) receptors of T cells thereby upregulating the immune system to more effectively detect and target cancer. Myasthenia gravis (MG) is a reported side effect of this medication. Our patient is an 87-year-old male with urothelial cell bladder cancer who developed MG following the administration of pembrolizumab and was treated with plasma exchange therapy. We aim to examine the existing literature concerning treatments for MG, with a particular focus on myasthenia gravis induced by pembrolizumab. We will discuss the occurrence rates and results of such instances, along with their implications for the future of these potential therapies.

Для цитирования: Kosick Thomas I, Patel Krima, Jasinski Jacob, Dada Bolanle. A Case of Pembrolizumab-Induced Myasthenia Gravis.. Cureus. 2023. DOI: 10.7759/cureus.45455.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.